



Osaka Securities Exchange (Hercules Market)

July 29, 2009

To All Concerned Parties

Company Name: en-japan inc.
(Stock Code: 4849)
Representative: President Takatsugu Suzuki
Contact: Managing Director, Administrative Office
Shinichi Yamazaki
(TEL. 03-3342-4506)

Notice Concerning Capital and Business Alliance

At a Board of Directors meeting held on July 29, 2009, en-japan inc. ("the Company") resolved to conclude a Basic Agreement concerning fundamental items pertaining to an investment in and business alliance with Pharma Network Co., Ltd. (Head Office: Chuo-ku, Tokyo; Kenshi Ichiki, President; "Pharma Network").

Moreover, at its Board of Directors meeting today, Pharma Network resolved to merge with EP Medical Co., Ltd. (Head Office: Tokyo; Enokido Makoto, President; "EP Medical"). Details are provided below.

Details

1. Purpose of the capital and business alliance

As the recession triggered by the global economic downturn continues, the scale of the pharmaceuticals market is expanding along with the full-scale shift to longer lives and the graying of society. The CSO (Contract Sales Organization) industry in particular, which is engaged in businesses such as specific dispatch of MR (Medical Representatives) and subcontracting, is expanding steadily and has become a sector where future growth is anticipated.

Because Pharma Network and EP Medical are developing their businesses centered on CSO, Pharma Network, the new company formed through a merger, has an excellent opportunity to grow stably in the future (EP Medical, the surviving entity of the merger, will change its trade name to Pharma Network Co., Ltd. at the time of the merger). A critical issue for the new company's growth, however, will be to secure and retain high-caliber human resources. Based on their recognition that both parties will be able to anticipate further growth if the Company, which possesses unique knowledge and experience in the hiring and employment sector, provides human resources employment support and education and training programs to address this issue, the two companies have agreed to an alliance.

Based on the conclusion of this Basic Agreement, both firms will pursue further discussions concerning the specific details and seek to realize the benefits of the alliance as quickly as possible.

2. Summary of the investment

The Company will conclude a Share Transfer Agreement dated July 29 with the

shareholders of Pharma Network, and accept a transfer of Pharma Network shares.

- (1) Acquisition price 248,378,000 yen
 (2) Transfer date August 31, 2009 (provisional)

3. Capital and business alliance

Pharma Network and EP Medical will request approval of the merger agreement at extraordinary meetings of shareholders of the two companies scheduled to be held on August 20, 2009, and plan to merge on October 1.

The Company will become a shareholder of the new company to be formed by the merger, by acquiring the shares of Pharma Network as indicated in Section 2 above.

Because Pharma Network, the new company formed through the merger, will engage in the CSO business centered on the specific dispatch of MR, subcontracting and other businesses, the Company plans to provide human resources employment support and training support following the merger.

4. Summary of the capital and business alliance counterparty (Pharma Network)

(as of December 31, 2008)

(1) Company name	Pharma Network Co., Ltd.	
(2) Representative	Kenshi Ichiki, President	
(3) Head office	Chuo-ku, Tokyo	
(4) Foundation	August 18, 2000	
(5) Business description	Specific dispatch of MR to pharmaceutical and medical care-related firms and other businesses	
(6) Capital	288,625 thousand yen	
(7) Fiscal Year End	December 31	
(8) Employees	170 (as of March 31, 2009)	
(9) Major Shareholders	Name/Organization Name	Ownership Ratio
	Tokyo NVCC Limited Partnership for Investment	10.77%
	Minoru Abe	7.54%
	Toho Pharmaceutical Co.,Ltd	7.00%
(10) Relationship with the Company	Equity relationships	Not applicable.
	Personal relationships	Not applicable.
	Business relationships	Pharma Network has placed advertisements on the Company websites in the past.
	Related party circumstances	Not applicable.

(11) Operating Results for the Most Recent Fiscal Years (Unit : thousand yen)

Fiscal Year	FY2006/12	FY2007/12	FY2008/12
Net Sales	1,427,012	2,081,899	2,090,705
Operating Income	110,926	152,952	66,495
Ordinary Income	109,467	153,767	70,642
Net Income	186,029	89,701	36,753

5. Future schedule

July 29, 2009	Corporate resolution
July 29, 2009	Signing of Basic Agreement and Share Transfer Agreement
August 31, 2009	Share transfer date (provisional)

6. Future outlook

Pharma Network, the new company formed by the merger, will be an affiliate of the Company accounted for by the equity method. At the present time the affect of this alliance on the Company's operating results for the current fiscal year is projected to be immaterial. If it judges the alliance will have a crucial affect on operating results in the future, the Company will report promptly to that effect.

End